People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Other Health Care, Biotechnology, Other, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| NeuroPace Inc | — | Other Health Care | Series C | $208.6M | $1.5B | 2016 |
| Avedro Inc | — | Other Health Care | Series C | $158.4M | $571.6M | 2018 |
| Roka BioScience, Inc. | — | Biotechnology | Series B | $141.4M | $893.0M | 2013 |
| Vanqua Bio, Inc. | — | Biotechnology | Series C | $136.0M | $462.4M | 2019 |
| Adicet Bio, Inc. | — | Biotechnology | Series C | $116.8M | $3.3B | 2015 |
| Audentes Therapeutics, Inc. | — | Biotechnology | Series C | $107.5M | $2.7B | 2014 |
| Enobia Pharma Corp | — | Biotechnology | Series C | $100.0M | $819.2M | 2009 |
| Cerapedics Inc | — | Biotechnology | Series B | $99.1M | $491.7M | 2009 |
| Dfine Inc | — | Other | Series B | $77.3M | $290.6M | 2010 |
| scPharmaceuticals Inc. | — | Pharmaceuticals | Series C | $71.8M | $1.6B | 2016 |
Jonathan Silverstein at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jonathan Silverstein on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kush Parmar | 2 | 10 |
| Thomas Schuetz | 2 | 4 |
| Carl Gordon | 1 | 24 |
| Robert Anderson | 1 | 24 |
| Asish Xavier | 1 | 18 |
| Garheng Kong | 1 | 16 |
| Fred Cohen | 1 | 12 |
| Rishi Gupta | 1 | 12 |
| Jonathan Leff | 1 | 11 |
| Nael Kassar | 1 | 11 |
| Russell Hirsch | 1 | 10 |
| Chau Khuong | 1 | 9 |
| James Blair | 1 | 8 |
| Stephen Squinto | 1 | 8 |
| Greg Garfield | 1 | 8 |
| Csaba Truckai | 1 | 7 |
| Erez Chimovits | 1 | 7 |
| Michal Silverberg | 1 | 7 |
| Reza Zadno | 1 | 7 |
| James Sullivan | 1 | 7 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.